Testing a new medication for fatty liver disease

Plain-English translation of NCT06836609 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This is an early-stage study testing a new medication called in people with fatty liver disease. Researchers want to understand if the medication is safe, what side effects it might cause, and how it works to reduce fat buildup in the liver. The study has two parts: one for people with fatty liver disease, and another for people with a more serious form that includes liver inflammation.

Fatty liver disease caused by metabolic problems like obesity and diabetes is becoming increasingly common, but there are few effective treatments. This medication aims to help reduce the amount of fat in the liver and potentially prevent the disease from getting worse.

Do you qualify?

You likely qualify if…

you are between 18–55 years old (Part A) or 18–65 years old (Part B)
you have been diagnosed with fatty liver disease or fatty liver disease with inflammation
you have a body mass index (BMI) between 30 and 40
you have significant fat buildup in your liver, confirmed by imaging tests
if you take blood pressure, cholesterol, or diabetes medications, you have been on a stable dose for at least 12 weeks

You likely don't qualify if…

you have cirrhosis or advanced liver disease
you have other types of chronic liver disease (such as hepatitis B or C)
you have had liver injury from medications in the past year
you have had a liver transplant or are on a transplant waiting list
you cannot have an MRI scan due to metal implants, pacemakers, or other medical reasons

What participation looks like

You will receive a single dose (Part A) or two doses (Part B) of the medication or a placebo, and researchers will monitor you closely with blood tests and imaging scans to check how the medication affects your liver and whether you experience any side effects. You'll have multiple follow-up visits over several weeks or months to measure liver fat content, blood levels of the medication, and overall safety.

AI-generated summary from trial data · Jul 9, 2026 · Not medical advice

Testing a new medication for fatty liver disease

What is this trial?

Do you qualify?

What participation looks like

Trial locations